Fig. 1From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trialsFlow chart showing the study selection and reasons for the excluded studies [33,34,35,36,37]Back to article page